Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2013-11-15 Regulatory Filings
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2013
Regulatory Filings Classification · 100% confidence The document is a Form 12B-25, which is a Notification of Late Filing for a Form 10-Q quarterly report. It explicitly states that the quarterly report for the period ended September 30, 2013, has not been completed due to administrative delays and will be filed soon. The document does not contain the actual financial data or substantive financial analysis of the 10-Q report itself, but rather is a regulatory notification about the delay in filing. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document and not the report itself.
2013-11-15 English
FORM SC 13G/A
Major Shareholding Notification
2013-09-24 English
SC 13G
Major Shareholding Notification
2013-09-24 English
Interim / Quarterly Report 2013
Interim / Quarterly Report Q2 2013
2013-08-19 English
Interim / Quarterly Report 2013
Interim / Quarterly Report Q1 2013
2013-08-19 English
Regulatory Filings 2013
Regulatory Filings Classification · 100% confidence The document is a Form 12B-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2013, due to administrative delays, and anticipates filing it soon. The document does not contain the actual financial data or the report itself, but is an announcement regarding the delay in filing the 10-Q. The document length is short (2103 characters), consistent with a notification rather than a full report. Therefore, this is a Regulatory Filing (RNS) as it is a compliance notification and does not contain substantive financial data or the report itself.
2013-08-13 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.